News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research> BofAS: Akeso (09926.HK) Cadonilimab Records MoM Growth Against Seasonality
BofAS issued a report stating that Akeso (09926.HK)'s cadonilimab recorded MoM growth against seasonality. In February, Akeso's sample drug sales amounted to RMB71.3 million, repre...
Reset
Send
The window will close in 5 seconds
<Research> BofAS: Akeso (09926.HK) Cadonilimab Records MoM Growth Against Seasonality
Close
Recommend
6
Positive
7
Negative
4
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

BofAS issued a report stating that Akeso (09926.HK)  -3.400 (-2.833%)    Short selling $132.92M; Ratio 22.332%   's cadonilimab recorded MoM growth against seasonality. In February, Akeso's sample drug sales amounted to RMB71.3 million, representing a YoY increase of 319.6%. Among which, cadonilimab sales reached RMB44.3 million, up 249.5% YoY and 9.6% MoM, achieving positive sequential growth during the Lunar New Year holiday period. Monthly sales of ivonescimab reached RMB26.6 million, continuing its volume expansion, with a YoY increase of 517.4%.The Buy rating on Akeso is maintained, with a TP of HKD162.8. (ha/a)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-22 16:25.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.